Abstracts tagged "Adalimumab"

Abstract Number: 2173 • 2012 ACR/ARHP Annual Meeting
Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Navarro Sarabia F¹, Francisco J. Blanco V², Álvaro Gracia JM³, JA García Meijide⁴ and Jl Poveda⁵, ¹Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Rheumatology Service, H. Universitario La Princesa, Madrid, SC, Spain, ⁴Rheumatologist Service, Hospital Ntra. Sra. La Esperanza, Santiago de Compostela, Spain, ⁵Pharmacy Service, Hospital Universitario La Fe, Valencia, Spain
Background/Purpose: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocilizumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in reducing signs and…
Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…
Abstract Number: 580 • 2012 ACR/ARHP Annual Meeting
Changes in Sclerostin, Dickkopf-1 and Serum Markers of Inflammation, Cartilage and Bone Turnover in Patients with Axial Spondyloarthritis Treated with Adalimumab
Susanne Juhl Pedersen¹, Inge Juul Sørensen², Julia S. Johansen³, Patrick Garnero⁴, Anne Gitte Loft⁵, Jens Skoedt⁶, Gorm Thamsborg⁷, Karsten Asmussen⁸, Elka Kluger⁹, Jesper Nørregaard¹⁰, Torben Grube Christensen¹¹ and Mikkel Østergaard¹², ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Department of Rheumatology, Hvidovre Hospital, Copenhagen, Denmark, ³Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark, ⁴INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ⁵Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ⁶Department of Rheumatology, Gentofte Hospital, Copenhagen, Denmark, ⁷Dep. of Rheumatology, Glostrup Hospital, Copenhagen, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁹King Christian 10th Rheumatism Hospital at Gråsten, Graasten, Denmark, ¹⁰Dep of Rheumatology, Hørsholm Hospital, Hørsholm, Denmark, ¹¹Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹²Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Few studies have investigated changes in plasma sclerostin and Dickkopf1 (DKK-1) in relation to other biomarkers of inflammation, cartilage and bone turnover during treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].